|
Tuesday, November 18, 2014
Print Current Day:
 |
|
| SESSION 1 SCHEDULE | |
|
Tuesday
SESSION 1:
PROGRESS IN TRANSCATHETER HEART VALVES AND NEW APPROACHES TO ASCENDING AORTIC DISEASE
Moderators:Edward B. Diethrich, MD / Ali Khoynezhad, MD, PhD
|
|
| x | |
| 6:49 AM - 6:53 AM | Opening Remarks |
| Presenter(s):Frank J. Veith, MD | |
| View Abstract | |
| 6:53 AM - 6:58 AM | Cerebral Protection Techniques And Devices For Use In Transcatheter Aortic Valve Replacement (TAVR) And TEVAR: The Embrella And Claret Medical Sentinal Devices And Others: How Well Do They Work |
| Presenter(s):Jeffrey P. Carpenter, MD | |
| View Abstract | |
| 6:59 AM - 7:04 AM | Status Of Left Atrial Appendage Occlusive Devices In 2014 |
| Presenter(s):Ted Feldman, MD | |
| View Abstract | |
| 7:05 AM - 7:10 AM | Trans-Carotid Access For TAVR: Value, Technique And Limitations |
| Presenter(s):Erno Remsey-Semmelweis, MD, PhD | |
| View Abstract | |
| 7:11 AM - 7:16 AM | Status Of Transcatheter Mitral Valve Repair: Where Is It Heading |
| Presenter(s):Ted Feldman, MD | |
| View Abstract | |
| 7:17 AM - 7:22 AM | Role And Value Of TAVR Today And In The Future |
| Presenter(s):Allan Stewart, MD | |
| View Abstract | |
| ASCENDING AORTIC LESIONS | |
| 7:23 AM - 7:28 AM | New Simplified Concept For Constructing Branched Endografts From Standardized Components: How It Can Be Used For TAAAs, Arch Lesions And Hypogastric Revascularization |
| Presenter(s):Patrick W. Kelly, MD | |
| View Abstract | |
| 7:29 AM - 7:34 AM | Endovascular Approaches To The Ascending Aorta For Repair With A Branched Endograft: Techniques And When Is It Feasible And For What Lesions |
| Presenter(s):Tilo Koelbel, MD, PhD | |
| View Abstract | |
| 7:35 AM - 7:40 AM | Innovative Approaches And Future Horizons To Ascending Aortic Pathologies: What Can Be Done And What Problems Remain |
| Presenter(s):Ralf R. Kolvenbach, MD | |
| View Abstract | |
| 7:41 AM - 7:46 AM | Tips, Tricks And Results With Endograft Repair Of Ascending Aortic Lesions |
| Presenter(s):Grayson H. Wheatley, MD / Edward B. Diethrich, MD | |
| View Abstract | |
| 7:47 AM - 7:52 AM | Hemodynamic And Anatomical Challenges To Overcome With Endovascular Grafts In The Ascending Aorta |
| Presenter(s):Robert J. Hinchliffe, MD | |
| View Abstract | |
| 7:53 AM - 7:58 AM | Experience With Ascending Aortic Endografts Using An FDA IDE Approved Device: What Has Been Done, What Lesions Can Be Treated And What Challenges Remain |
| Presenter(s):Ali Khoynezhad, MD, PhD | |
| View Abstract | |
| 7:59 AM - 8:05 AM | Panel Discussion |
| END OF SESSION 1 | |
| SESSION 2 SCHEDULE | |
|
Tuesday
SESSION 2:
NEW DEVELOPMENTS IN THE TREATMENT OF AORTIC ARCH LESIONS AND DISSECTIONS
Moderators:Timothy A.M. Chuter, DM / Hazim J. Safi, MD
|
|
| x | |
| 8:06 AM - 8:11 AM | For Arch Lesions In Situ Fenestration Is Still Viable: New Techniques Will Facilitate This Approach |
| Presenter(s):Bjõrn Sonesson, MD, PhD | |
| View Abstract | |
| 8:12 AM - 8:17 AM | Results Of Branched Endografts For Repair Of Aortic Arch Lesions: Based On A Chinese Multicenter Study |
| Presenter(s):Qingsheng Lu, MD / Zaiping Jing, MD | |
| View Abstract | |
| 8:18 AM - 8:23 AM | Mid-Term Outcomes Of A Simplified Method Of Arch Aneurysm Treatment Using A Precurved Fenestrated Aortic Endograft: Technique And Results |
| Presenter(s):Yoshihiko Yokoi, MD | |
| View Abstract | |
| MEGADEBATE | |
| 8:24 AM - 8:29 AM | DEBATE: Total Endovascular Aortic Arch Repair Is Feasible And Will Be The Best Method: Technique And Early Results |
| Presenter(s):Stephan Haulon, MD | |
| View Abstract | |
| 8:30 AM - 8:35 AM | DEBATE: Hybrid (Open And Endo) Repair Is The Best Treatment For Aortic Arch Lesions: Tips And Tricks |
| Presenter(s):Germano Melissano, MD | |
| View Abstract | |
| 8:36 AM - 8:41 AM | DEBATE: Value And Limitations Of Chimney Grafts To Treat Arch Lesions: When Are They Best: Based On An 11-Year Experience |
| Presenter(s):Nicola Mangialardi, MD | |
| View Abstract | |
| 8:42 AM - 8:47 AM | DEBATE: Total Endovascular Arch Replacement With Sandwich Grafts, And TEVAR Is Often The Simplest And Best Treatment For Arch Lesions |
| Presenter(s):Armando C. Lobato, MD, PhD | |
| View Abstract | |
| 8:48 AM - 8:53 AM | DEBATE: Open Repair Is Still The Best Treatment For Most Arch Lesions |
| Presenter(s):Joseph S. Coselli, MD | |
| View Abstract | |
| 8:54 AM - 8:59 AM | Total Endovascular Arch Repair For Arch Aneurysms And Dissections: Comparison Of Bolton Double Branch Endograft vs. Hybrid Debranching With TEVAR |
| Presenter(s):Toru Kuratani, MD, PhD | |
| View Abstract | |
| 9:00 AM - 9:05 AM | A New Classification System For Type B Aortic Dissection (TBAD): It Will Help Predict The Probability Of Visceral Malperfusion And Reverse Aortic Remodeling After TEVAR |
| Presenter(s):Ali Khoynezhad, MD, PhD | |
| View Abstract | |
| 9:06 AM - 9:13 AM | Panel Discussion |
| END OF SESSION 2 | |
| SESSION 3 SCHEDULE | |
|
Tuesday
SESSION 3:
TYPE B AORTIC DISSECTIONS (TBADs) AND THEIR TREATMENT
Moderators:Richard P. Cambria, MD / Juan C. Parodi, MD
|
|
| x | |
| 9:13 AM - 9:18 AM | New MR Imaging Techniques (4D) To Measure Vascular Hemodynamics And Biomechanics: How Can They Help In Treating Patients With TBADs |
| Presenter(s):Rachel E. Clough, MD, PhD | |
| View Abstract | |
| 9:19 AM - 9:24 AM | Tips And Tricks For Avoiding Pitfalls In The TEVAR Treatment Of TBADs: Based On Experience In More Than 1800 Patients |
| Presenter(s):Wei Guo Fu, MD | |
| View Abstract | |
| FOUR-WAY DEBATE | |
| 9:25 AM - 9:30 AM | DEBATE: All “Uncomplicated” TBADs Should Be Treated Early By TEVAR Since All Are Or Will Become Complicated: INSTEAD XL And IRAD Prove It And We Don’t Need Further Trials |
| Presenter(s):Christoph A. Nienaber, MD, PhD | |
| View Abstract | |
| 9:31 AM - 9:36 AM | DEBATE: Why We Still Need A Randomized Controlled Trial (RCT) Of Intensive Medical Therapy vs. Early TEVAR For Uncomplicated TBAD |
| Presenter(s):Frank A. Lederle, MD | |
| View Abstract | |
| 9:37 AM - 9:42 AM | DEBATE: Medical Therapy And Close Observation Is Best For Uncomplicated TBAD: When Complications Arise, Most Patients Are Best Treated With Open Operation: Long-Term Results (>20 Years) Justify It |
| Presenter(s):Hazim J. Safi, MD / Ali Azizzadeh, MD | |
| View Abstract | |
| 9:43 AM - 9:48 AM | DEBATE: With Patients Having Uncomplicated TBAD Medical Treatment With Delayed (2-3 Months) TEVAR Is The Best Treatment: It Will Lessen Complications Including Retrograde Type A Dissections |
| Presenter(s):Matt M. Thompson, MD | |
| View Abstract | |
| 9:49 AM - 9:54 AM | Current Single Center Results Of Medically Treated TBAD Patients |
| Presenter(s):Mark Conrad, MD, MMSc / Richard P. Cambria, MD | |
| View Abstract | |
| 9:55 AM - 10:00 AM | Why We Need A New Classification System For Patients With TBAD: What Is It |
| Presenter(s):Christoph A. Nienaber, MD, PhD / Michael D. Dake, MD | |
| View Abstract | |
| 10:01 AM - 10:10 AM | Panel Discussion |
| 10:10 AM - 10:30 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 3 | |
| SESSION 4 SCHEDULE | |
|
Tuesday
SESSION 4:
NEW DEVELOPMENTS IN TEVAR AND THE MANAGEMENT OF TBAD PATIENTS
Moderators:Christoph A. Nienaber, MD, PhD / Michael D. Dake, MD
|
|
| x | |
| 10:30 AM - 10:35 AM | Management Of Distal Re-entry Tears After TEVAR For TBAD: When Is It Necessary And How To Do It |
| Presenter(s):Qingsheng Lu, MD / Zaiping Jing, MD | |
| View Abstract | |
| 10:36 AM - 10:41 AM | In Patients With Acute TBADs When Is TEVAR Closure Of Proximal Entry Tears Sufficient And When Is Adjunctive Treatment Necessary: What Adjunctive Procedures Can Be Used |
| Presenter(s):Jean-Marc Alsac, MD, PhD | |
| View Abstract | |
| 10:42 AM - 10:47 AM | Endovascular Options To Obliterate The Patent False Lumen When Coverage Of The Primary Tear Does Not Do So: New Data On Safety And Efficacy Of These Options |
| Presenter(s):Peter J. Mossop, MBBS | |
| View Abstract | |
| 10:48 AM - 10:53 AM | Is The Petticoat Technique (Proximal Covered Stent And Distal Bare Stent) Effective In Treating Acute And Chronic TBADs: 3-Year Results Of The STABLE I And II Trials: Are Long-Term Outcomes Better |
| Presenter(s):Joseph V. Lombardi, MD | |
| View Abstract | |
| 10:54 AM - 10:59 AM | DEBATE: Value And Limitations Of Using Fenestrated And Branched Endografts (F/B EVAR) To Treat Chronic TBADs With Infradiaphragmatic AAAs: It Is The Way To Go |
| Presenter(s):Eric L.G. Verhoeven, MD, PhD / Piotr M. Kasprzak, MD | |
| View Abstract | |
| 11:00 AM - 11:05 AM | DEBATE: What Is Wrong With TEVAR To Treat Chronic TBADs |
| Presenter(s):Nicholas J.W. Cheshire, MD / Richard G.J. Gibbs, FRCS | |
| View Abstract | |
| 11:06 AM - 11:11 AM | When After An Acute TBAD Does The Dissection Flap Become Fixed: Based On Dynamic (4D) CTA And MRA |
| Presenter(s):Alan B. Lumsden, MD, FACS | |
| View Abstract | |
| 11:12 AM - 11:17 AM | Objective Assessment Of Current Endografts For TEVAR: Which Grafts For Which Lesion And Which Anatomy: It Makes A Difference |
| Presenter(s):Ludovic Canaud, MD, PhD | |
| View Abstract | |
| 11:18 AM - 11:25 AM | Panel Discussion |
| Moderator(s): Kim J. Hodgson, MD / Jan S. Brunkwall, MD, PhD | |
| 11:25 AM - 11:30 AM | Pathophysiological Mechanism For False Lumen Enlargement To Form An Aneurysm After A TBAD: What Can Be Done To Prevent It |
| Presenter(s):Ramon Berguer, MD, PhD | |
| View Abstract | |
| 11:31 AM - 11:36 AM | Late Remodeling In Stented And Unstented Aortic Segments After TEVAR For Complex TBADs |
| Presenter(s):Mark Conrad, MD, MMSc / Richard P. Cambria, MD | |
| View Abstract | |
| 11:37 AM - 11:42 AM | Intensive Follow-up With CTA Imaging Surveillance Is Needed For TEVAR To Be Successful Treatment Of TBAD Patients |
| Presenter(s):Götz M. Richter, MD, PhD | |
| View Abstract | |
| 11:43 AM - 11:48 AM | Long-Term (20-Year) Results Of Open Repair Of Chronic TBADs With Aneurysm Formation Are Good: It Should Be The Gold Standard Of Care |
| Presenter(s):Hazim J. Safi, MD | |
| View Abstract | |
| 11:49 AM - 11:54 AM | Branched Endografts For Treating Chronic TBAD With Aneurysm Formation: Advantages And Limitations |
| Presenter(s):Marcelo Ferreira, MD | |
| View Abstract | |
| 11:55 AM - 0:00 AM | Panel Discussion |
| 12:00 PM - 1:00 PM | Lunch Break – 2nd Floor Promenade Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 4 | |
| SESSION 5 SCHEDULE | |
|
Tuesday
SESSION 5:
IN HONOR OF JAMES A. DEWEESE, MD: NEW DEVELOPMENTS IN THE MANAGEMENT OF PATIENTS WITH CAROTID DISEASE
Moderators:Wesley S. Moore, MD / Frank J. Veith, MD
|
|
| x | |
| 1:00 PM - 1:05 PM | Tips And Tricks To Make CAS Safer: Lessons Learned After More Than 3000 Procedures |
| Presenter(s):Klaus D. Mathias, MD | |
| View Abstract | |
| 1:06 PM - 1:11 PM | CAS Recanalization For Total ICA Occlusions: Long-Term Clinical And Image Follow-up: When Are The Procedures Worthwhile: A New Horizon |
| Presenter(s):Paul H.L. Kao, MD | |
| View Abstract | |
| 1:12 PM - 1:17 PM | Diagnosis And Prophylactic Treatment Of Vulnerable Plaques: Can Their Vulnerability Be Decreased By Stenting |
| Presenter(s):Gregg W. Stone, MD | |
| View Abstract | |
| 1:18 PM - 1:23 PM | What Is The Current Evidence For Decreasing The Incidence Of Strokes On Medical Treatment Alone: Don’t Believe The NY Times – Statins Are Safe And Should Be Used More Widely |
| Presenter(s):Richard Bulbulia, MA, MD, FRCS | |
| View Abstract | |
| 1:24 PM - 1:29 PM | What Constitutes Best Medical Treatment (BMRx) Currently In Asymptomatic Carotid Stenosis: What Happens To Carotid Plaques On BMRx |
| Presenter(s):J. David Spence, MD | |
| View Abstract | |
| 1:30 PM - 1:35 PM | Long-Term Results Of SAMMPRIS Trial In Patients With Intracranial Stenoses: What Does It Tell Us About The Feasibility And Value Of BMRx |
| Presenter(s):Colin P. Derdeyn, MD / Marc I. Chimowitz, MBChB | |
| View Abstract | |
| 1:36 PM - 1:41 PM | Increased Cardiovascular Mortality In Patients With Asymptomatic Carotid Stenosis Who Are Not On Statins: What Should Optimal Medical Therapy Be And Can It Decrease Plaque Size And Danger |
| Presenter(s):Andrew N. Nicolaides, MS / Stavros Kakkos, MD, PhD / | |
| View Abstract | |
| 1:42 PM - 1:48 PM | Panel Discussion |
| Moderator(s): Daniel G. Clair, MD / Jean-Pierre Becquemin, MD, FRCS | |
| 1:48 PM - 1:53 PM | Update On The ACT I Trial: A RCT Comparing CAS vs. CEA In Patients With Asymptomatic High-Grade Carotid Stenosis |
| Presenter(s):Jon S. Matsumura, MD | |
| View Abstract | |
| 1:54 PM - 1:59 PM | DEBATE: Medical Treatment Is Best For Patients With High-Grade Asymptomatic Carotid Stenosis (Asx CS) |
| Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
| View Abstract | |
| 2:00 PM - 2:05 PM | DEBATE: Carotid Endarterectomy (CEA) Is The Best Treatment For Most Patients With High-Grade Asx CS |
| Presenter(s):Richard P. Cambria, MD | |
| View Abstract | |
| 2:06 PM - 2:11 PM | DEBATE: Carotid Stenting (CAS) Is The Best Treatment For Most Patients With High-Grade Asx CS |
| Presenter(s):William A. Gray, MD | |
| View Abstract | |
| 2:12 PM - 2:17 PM | Early Results From The ACST-2 Trial: In >1500 Patients CAS And CEA Appear To Be Equivalent Treatments For Asx CS |
| Presenter(s):Alison Halliday, MS, FRCS | |
| View Abstract | |
| 2:18 PM - 2:23 PM | What Will CREST 2 Tell Us And When: We Must Compare CAS And CEA vs. Current Medical Treatment In Patients With Asx CS In A RCT |
| Presenter(s):Thomas G. Brott, MD | |
| View Abstract | |
| 2:24 PM - 2:29 PM | What Will SPACE 2 Tell Us And When: We Must Compare CAS And CEA vs. Current Medical Treatment In Patients With Asx CS In A RCT |
| Presenter(s):Hans-Henning Eckstein, MD, PhD | |
| View Abstract | |
| 2:26 PM - 2:41 PM | DEBATE: Based On The CREST RCT And Other Data, CAS Is The Best Treatment For Most Patients With Sx CS If The Right Techniques Are Used In Experienced Centers |
| Presenter(s):Horst Sievert, MD | |
| View Abstract | |
| 2:30 PM - 2:35 PM | DEBATE: Based On The CREST RCT And Other Data, CEA Seems To Be The Best Treatment For Symptomatic Carotid Stenosis (Sx CS) In Most Patients |
| Presenter(s):Wesley S. Moore, MD | |
| View Abstract | |
| 2:42 PM - 2:50 PM | Panel Discussion |
| 2:50 PM - 3:05 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 5 | |
| SESSION 6 SCHEDULE | |
|
Tuesday
SESSION 6:
MORE ON THE MANAGEMENT OF PATIENTS WITH CAROTID DISEASE
Moderators:Glenn M. LaMuraglia, MD / Thomas S. Riles, MD
|
|
| x | |
| 3:05 PM - 3:10 PM | Resolving The Differences Between Various CAS/CEA Guidelines – All Based On The Same Data: How Could They Be So Different |
| Presenter(s):Anne L. Abbott, MD, PhD, FRACP | |
| View Abstract | |
| 3:11 PM - 3:16 PM | How To Optimize Brain Safety With CAS And CEA: What Is The Significance Of Silent MRI Defects |
| Presenter(s):Laura Capoccia, MD, PhD | |
| View Abstract | |
| 3:17 PM - 3:22 PM | Microemboli And DW MRI Defects After Carotid Interventions: Do They Impair Cognitive Function |
| Presenter(s):Wei Zhou, MD | |
| View Abstract | |
| 3:23 PM - 3:28 PM | Can Asx CS Lead To Cognitive Impairment: Does Carotid Revascularization Produce Cognitive Improvement |
| Presenter(s):Brajesh K. Lal, MD | |
| View Abstract | |
| 3:29 PM - 3:34 PM | Proximal Brain Protection With Flow Reversal vs. Filter Protection For CAS: Which Is Better And How Best To Achieve Flow Reversal |
| Presenter(s):Claudio J. Schonholz, MD | |
| View Abstract | |
| 3:35 PM - 3:40 PM | Flow Reversal Brain Protection Can Be Achieved During CAS With A Modified Mo.Ma Device: How To Do It |
| Presenter(s):Juan C. Parodi, MD | |
| View Abstract | |
| EARLY TREATMENT OF SX CS | |
| 3:41 PM - 3:46 PM | Is CEA Within 48 Hours Of Acute Symptom Onset Safe: The Evidence Is Mixed |
| Presenter(s):Martin Bjorck, MD, PhD | |
| View Abstract | |
| 3:47 PM - 3:52 PM | CEA Early After Symptom Onset Does Not Increase Risk: Not So With CAS |
| Presenter(s):Gustav Fraedrich, MD | |
| View Abstract | |
| 3:53 PM - 3:58 PM | DEBATE: Expedited CEA In Symptomatic CS Patients: How Long Post Symptom Onset Can Patients Safely Undergo CEA |
| Presenter(s):Ross Naylor, MD, FRCS | |
| View Abstract | |
| 3:59 PM - 4:04 PM | DEBATE: Early CAS After Symptom Onset Is Safe In Younger Patients Under Certain Conditions |
| Presenter(s):Klaus D. Mathias, MD | |
| View Abstract | |
| 4:05 PM - 4:12 PM | Panel Discussion |
| END OF SESSION 6 | |
| SESSION 7 SCHEDULE | |
|
Tuesday
SESSION 7:
MORE ON THORACIC AND THORACOABDOMINAL ANEURYSMS (TAAAs); PREVENTING SPINAL CORD ISCHEMIA (SCI)
Moderators:Larry H. Hollier, MD / Timothy A.M. Chuter, DM
|
|
| x | |
| 4:12 PM - 4:17 PM | Paraplegia Following Fenestrated And Branched Aortic Endografts (F/B EVAR): Incidence, Severity And Ways To Prevent |
| Presenter(s):Richard G. McWilliams, FRCR, EBIR | |
| View Abstract | |
| 4:18 PM - 4:23 PM | Incidence And Treatment Of SCI After TEVAR: Role Of Pressure Controlled Automatic Spinal Fluid Drainage (Liquo Guard System) |
| Presenter(s):Germano Melissano, MD | |
| View Abstract | |
| 4:24 PM - 4:29 PM | Value Of Neuromonitoring During Open And Endo TAAA Repairs: How To Do It |
| Presenter(s):Michael J. Jacobs, MD | |
| View Abstract | |
| 4:30 PM - 4:35 PM | Vascular Specialists Doing TEVAR May Be Underestimating The Paraplegia Risk: Pearls To Keep In Mind From A Senior TAAA Surgeon |
| Presenter(s):Charles W. Acher, MD | |
| View Abstract | |
| 4:36 PM - 4:41 PM | Incidence, Clinical Features Of SCI Associated With Endovascular Repair Of TAAAs: How To Treat And Prevent This Complication |
| Presenter(s):Matthew J. Eagleton, MD | |
| View Abstract | |
| 4:42 PM - 4:47 PM | Best Approaches To Preventing SCI During TEVAR And Open Repair Of TAAAs: Pearls Regarding Etiology, Monitoring And Treating |
| Presenter(s):Hamdy Awad, MD / Patrick Vaccaro, MD | |
| View Abstract | |
| 4:48 PM - 4:53 PM | Panel Discussion |
| END OF SESSION 7 | |
| SESSION 8 SCHEDULE | |
|
Tuesday
SESSION 8:
MORE ON THORACIC AORTIC DISEASE, TEVAR AND TBADs
Moderators:Rodney A. White, MD / ShenMing Wang, MD, PhD
|
|
| x | |
| 4:54 PM - 4:59 PM | Ascending Aortic Complications Following TEVAR: How Can They Be Diagnosed And Treated Successfully |
| Presenter(s):Roberto Chiesa, MD | |
| View Abstract | |
| 5:00 PM - 5:05 PM | Periscope Endografts To Revascularize The Left Subclavian Artery (LSA) During TEVARs Covering Its Origin: Technique And Advantages |
| Presenter(s):Mario Lachat, MD | |
| View Abstract | |
| 5:06 PM - 5:11 PM | Can PET-CT Help To Indicate Which Uncomplicated TBAD Will Become Complicated: Should This Be An Indication For TEVAR |
| Presenter(s):Natzi Sakalihasan, MD, PhD | |
| View Abstract | |
| 5:12 PM - 5:17 PM | How To Manage Complications Of Malperfusion After Coverage Of The TBAD Primary Tear By TEVAR: Tips And Tricks |
| Presenter(s):Ali Azizzadeh, MD / Mohammad H. Eslami, MD, RVT / Hazim J. Safi, MD | |
| View Abstract | |
| 5:18 PM - 5:23 PM | Why The INSTEAD Trials Are Not Enough To Justify TEVAR For All Uncomplicated TBADs And Why We Need Additional Trials |
| Presenter(s):Firas F. Mussa, MD | |
| View Abstract | |
| 5:24 PM - 5:29 PM | Evaluation Of Dynamic Intimal Flap Movement In TBAD Patients: Effect Of TEVAR And How Important Is Time After Onset In Determining Flap Mobility |
| Presenter(s):Frank R. Arko, MD | |
| View Abstract | |
| 5:30 PM - 5:35 PM | Adjunctive False Lumen Techniques For Endovascular Repair Of Chronic TBADs: When Are They Needed |
| Presenter(s):Eric E. Roselli, MD | |
| View Abstract | |
| 5:36 PM - 5:41 PM | Relationship Between Aortic Morphology After TEVAR And Clinical Outcomes With TBADs |
| Presenter(s):Matt M. Thompson, MD | |
| View Abstract | |
| 5:41 PM - 5:46 PM | Tricks And Pitfalls For Antegrade Endograft Delivery During Open Repair Of Acute Type A Aortic Dissections |
| Presenter(s):Ourania Preventza, MD / Joseph S. Coselli, MD | |
| View Abstract | |
| 5:47 PM - 5:55 PM | Panel Discussion End of Program A |
| END OF SESSION 8 | |
| SESSION 9 SCHEDULE | |
|
Tuesday
SESSION 9:
LOWER EXTREMITY OCCLUSIVE DISEASE MANAGEMENT HOT TOPICS – NEW TECHNIQUES AND NEW DEVICES
Moderators:Enrico Ascher, MD / Frank B. Pomposelli, MD
|
|
| x | |
| 6:48 AM - 6:53 AM | Ultrasound Guidance To Decrease Access Site Complications: An Essential Tool Even For Experienced Interventionalists |
| Presenter(s):Peter A. Schneider, MD | |
| View Abstract | |
| 6:54 AM - 6:59 AM | Role Of Directional Atherectomy For Treatment Of Lower Extremity Occlusive Disease: Is There A Gender Effect |
| Presenter(s):Lawrence A. Garcia, MD | |
| View Abstract | |
| 7:00 AM - 7:05 AM | Advantages And Limitations Of The Tack-It Device System For Minimizing Dissection After Plain Old Balloon Angioplasty (POBA) And Leaving Minimal Metal Behind: The TOBA Study |
| Presenter(s):Marianne Brodmann, MD | |
| View Abstract | |
| 7:06 AM - 7:11 AM | Technical Tips And Tricks To Optimize The Performance And Outcomes With The Supera Stent And Probably All Stents: Proper Sizing, Avoiding Elongation And Adequate Predilitation Matter In Producing Good 3-Year Results |
| Presenter(s):D. Christopher Metzger, MD | |
| View Abstract | |
| 7:12 AM - 7:17 AM | How To Use Drug Eluting Stents (DES) In Infrapopliteal Bifurcations |
| Presenter(s):Konstantinos Katsanos, MSc, MD, PhD, EBIR | |
| View Abstract | |
| 7:18 AM - 7:23 AM | Use Of Collaterals For Access And Retrograde Wire Passage: How To Do It |
| Presenter(s):Jos C. van den Berg, MD, PhD | |
| View Abstract | |
| 7:24 AM - 7:29 AM | When And How To Treat Below The Ankle Occlusive Disease: What Percent Of CLI Patients Will Require It |
| Presenter(s):Roberto Ferraresi, MD | |
| View Abstract | |
| 7:30 AM - 7:35 AM | With Below Knee (BK) Chronic Total Occlusions (CTOs), Success Depends On Choosing The Right Tools And Techniques: What New Tools And Techniques Exist To Help With Pedal And Tibial Access Like 3 French Sheaths And Systems |
| Presenter(s):Andrej Schmidt, MD | |
| View Abstract | |
| 7:36 AM - 7:42 AM | Panel Discussion |
| END OF SESSION 9 | |
| SESSION 10 SCHEDULE | |
|
Tuesday
SESSION 10:
LOWER EXTREMITY HOT TOPICS – MORE NEW TECHNOLOGIES AND THE IMPORTANCE OF TECHNIQUE; DEBATES
Moderators:Kenneth Ouriel, MD, MBA / Gregg S. Landis, MD
|
|
| x | |
| 7:42 AM - 7:47 AM | DEBATE: For CLI: Endovascular Treatments Should Be Used First In 100% Of Patients |
| Presenter(s):Marc Bosiers, MD / Koen Deloose, MD | |
| View Abstract | |
| 7:48 AM - 7:53 AM | DEBATE: For CLI: Open Surgery Should Be Used First In Some Patients: Which Ones |
| Presenter(s):Firas F. Mussa, MD | |
| View Abstract | |
| 7:54 AM - 7:59 AM | Value Of Ultrasound Guided Pedal Access To Treat CLI: How Can It Facilitate Use Of The Diamond Back Atherectomy Device: How Best To Close The Puncture Site |
| Presenter(s):Jihad A. Mustapha, MD | |
| View Abstract | |
| 8:00 AM - 8:05 AM | How Do Stent Characteristics/Details And Technical Details Of PTA Balloon Usage Affect Outcomes And Incidence Of Restenosis: Oversizing Matters And Is Bad |
| Presenter(s):Dierk Scheinert, MD | |
| View Abstract | |
| 8:06 AM - 8:11 AM | How To Optimize Outcomes With SFA Interventions: Details Of Stent Design And Deployment Techniques Are Important In Determining Restenosis And Failure As Is Predilatation With An Uncoated Balloon Before DEBs |
| Presenter(s):Stefan Mueller-Hülsbeck, MD | |
| View Abstract | |
| 8:12 AM - 8:17 AM | DEBATE: Why In Treating BK CTOs It Is Best To Stay Intraluminal |
| Presenter(s):Marco G. Manzi, MD | |
| View Abstract | |
| 8:18 AM - 8:23 AM | DEBATE: Subintimal Angioplasty Is Very Useful And Often Unavoidable In Treating BK CTOs |
| Presenter(s):Amman Bolia, MD | |
| View Abstract | |
| 8:24 AM - 8:29 AM | 15-Year Trends In CLI Treatment And Major Amputation: Better Care Is Making A Difference: Is It Due To Better Interventional And Bypass Treatment: Does Increased CLI Spending Increase Limb Salvage And Decrease Amputation Rates |
| Presenter(s):Philip P. Goodney, MD, MS | |
| View Abstract | |
| 8:30 AM - 8:37 AM | Panel Discussion |
| END OF SESSION 10 | |
| SESSION 11 SCHEDULE | |
|
Tuesday
SESSION 11:
MORE LOWER EXTREMITY HOT TOPICS – NEW STENT AND DRUG ELUTING BALLOON (DEB) DATA; IMPACT AND COST ISSUES
Moderators:Joseph L. Mills, MD / Giancarlo Biamino, MD, PhD
|
|
| x | |
| 8:38 AM - 8:43 AM | Is There A Negative Effect Of Endovascular Failure On Bypass Outcomes: Is It Reality Or A Myth |
| Presenter(s):Michael S. Conte, MD | |
| View Abstract | |
| 8:44 AM - 8:49 AM | What Is The Effect Of Extensive Lesion Calcification On The Outcome Of DEB Treatment |
| Presenter(s):Gunnar Tepe, MD | |
| View Abstract | |
| 8:50 AM - 8:55 AM | Why Are DEBs Cost Effective For Treating CLI Patients |
| Presenter(s):Thomas Zeller, MD | |
| View Abstract | |
| 8:56 AM - 9:01 AM | How To Align Financial Incentives For The Doctor, The Hospital And The Payer (Insurance Company) To Provide The Best And Most Effective Care In The Least Costly Manner: Impact Of Expensive New Technologies And Reintervention Rates |
| Presenter(s):W. Charles Sternbergh III, MD | |
| View Abstract | |
| 9:02 AM - 9:07 AM | Tips And Tricks For Tibial Interventions For CLI |
| Presenter(s):Roberto Ferraresi, MD | |
| View Abstract | |
| 9:08 AM - 9:13 AM | What’s New With US Approved Drug Eluting Stents (DESs) In The SFA And Below |
| Presenter(s):Ron Waksman, MD | |
| View Abstract | |
| 9:14 AM - 9:19 AM | 5-Year Results And New Findings From The Zilver PTX RCT And Registry: Benefits Of DESs Are Durable And Value With In Stent Restenosis (ISR), Long Lesions And Diabetics |
| Presenter(s):Michael D. Dake, MD | |
| View Abstract | |
| 9:20 AM - 9:25 AM | 2-3-Year Results With EverFlex Helical Nitinol Stent In The SFA And The Popliteal Artery: Are The Benefits Durable |
| Presenter(s):Marc Bosiers, MD / Patrick Peeters, MD | |
| View Abstract | |
| 9:25 AM - 9:33 AM | Panel Discussion |
| 9:33 AM - 9:48 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 11 | |
| SESSION 12 SCHEDULE | |
|
Tuesday
SESSION 12:
IN HONOR OF ROBERT B. RUTHERFORD, MD: NEW DEVELOPMENTS IN THE TREATMENT OF LOWER EXTREMITY ISCHEMIA; CLI, STENTS AND DEBs
Moderators:Ali F. AbuRahma, MD / Dierk Scheinert, MD
|
|
| x | |
| FOR SFA AND POPLITEAL LESIONS | |
| 9:48 AM - 9:53 AM | Update On The Efficacy Of DEBs For SFA And Popliteal Artery Lesions: Why Some Trials Are Positive And Some Negative: Are Good Results Holding Up: GLOBAL IN.PACT Registry Results In >1400 Patients |
| Presenter(s):Gunnar Tepe, MD / Dierk Scheinert, MD | |
| View Abstract | |
| 9:54 AM - 9:59 AM | POBA And “Vanella” Bare Metal Stents (BMS) Have Merit In Some AK And BK Occlusive Lesions Reserving The Fancy And Costly Stuff For Special Situations |
| Presenter(s):Iris Baumgartner, MD | |
| View Abstract | |
| 10:00 AM - 10:05 AM | What Have We In The US Learned From Our European Colleagues About CLI Treatment That Can Be Used To Improve Patient Care In The US |
| Presenter(s):Craig M. Walker, MD | |
| View Abstract | |
| 10:06 AM - 10:11 AM | Stenting For Femoral And Popliteal Artery Lesions: Where Do We Currently Stand And What Problems Remain |
| Presenter(s):Erich Minar, MD | |
| View Abstract | |
| 10:12 AM - 10:17 AM | Role Of DEBs vs. DESs For SFA Lesions And Value Of Paclitaxel DEBs For Long SFA Lesions: Is There Level 1 Proof Of Benefit |
| Presenter(s):Thomas Zeller, MD | |
| View Abstract | |
| 10:18 AM - 10:23 AM | Paclitaxel Coated DEBs Are Better Than Uncoated Balloons In The SFA: 1-Year Results From The IN.PACT SFA I/II RCTs |
| Presenter(s):Peter A. Schneider, MD / John R. Laird, MD / Gunnar Tepe, MD | |
| View Abstract | |
| 10:24 AM - 10:29 AM | DEBs Are Effective For SFA Lesions: 1-Year Results From The LEVANT II RCT Show It To Be So With The Bard Lutonix DEB: Stents Were Rarely Needed |
| Presenter(s):Kenneth Rosenfield, MD / Dierk Scheinert, MD | |
| View Abstract | |
| 10:30 AM - 10:35 AM | Durability Of Paclitaxel Coated DEBs In The SFA: Long-Term (3-Year) Results Of The PACIFIER Trial |
| Presenter(s):Michael Werk, MD | |
| View Abstract | |
| 10:36 AM - 10:41 AM | Mid-Term Results From The Belgian IN.PACT Trial Of Paclitaxel Coated DEBs vs. POBA: What Is Special About This Trial |
| Presenter(s):Erik E. Debing, MD, PhD | |
| View Abstract | |
| 10:42 AM - 10:50 AM | Panel Discussion |
| FOR BK AND INFRAPOPLITEAL LESIONS | |
| Moderator(s): Michael S. Conte, MD / George H. Meier III, MD | |
| 10:50 AM - 10:55 AM | How Often After Tibial Interventions For CLI Are Reinterventions Required: We Need Better Primary Treatments: What Are The Cost Implications |
| Presenter(s):Nicolas A. Diehm, MD / Iris Baumgartner, MD | |
| View Abstract | |
| 10:56 AM - 11:01 AM | Single Center RCT Of IN.PACT Deep Paclitaxel Coated DEBs vs. Uncoated Balloons Shows Benefit For BK Lesions Causing CLI: 3-Year Results Of The DEBATE Trial |
| Presenter(s):Francesco Liistro, MD | |
| View Abstract | |
| 11:02 AM - 11:07 AM | Single Center Results With Paclitaxel Coated DEBs For Infrapopliteal Lesions Shows Benefits: What Are They |
| Presenter(s):Andrej Schmidt, MD / Dierk Scheinert, MD | |
| View Abstract | |
| 11:08 AM - 11:13 AM | A Multicenter RCT (IN.PACT DEEP) Comparing Paclitaxel Coated DEBs With Uncoated Balloons Fails To Show Benefit For The DEBs |
| Presenter(s):Thomas Zeller, MD | |
| View Abstract | |
| 11:14 AM - 11:19 AM | Why Do The SINGLE CENTER Trial And Other BK DEB Results Differ From The Multicenter Trial Results: All DEBs Are Not Equal Or Used Equally: A Critical Analysis Of All Data And Some 3-Year Results |
| Presenter(s):Francesco Liistro, MD | |
| View Abstract | |
| 11:20 AM - 11:25 AM | How To Explain Differing Results Of RCTs Of DEBs In BK And Infrapopliteal Lesions: When Will We Get DEBs For BK Lesions In The US |
| Presenter(s):Krishna J. Rocha-Singh, MD | |
| View Abstract | |
| 11:26 AM - 11:31 AM | DEBs: Are They A Breakthrough Technology Or Another Tool In The Box: Why Is There Still Uncertainty: Do The PACUBA Trial Results With SFA/POP In Stent Restenosis (ISR) Help |
| Presenter(s):Johannes Lammer, MD | |
| View Abstract | |
| 11:32 AM - 11:37 AM | How Long Is Restored Patency Needed In CLI Patients; What Leads To Increased Limb Salvage With Poor Patency: Importance Of Reintervention, DESs And DEBs |
| Presenter(s):Frank E.G. Vermassen, MD, PhD | |
| View Abstract | |
| 11:38 AM - 11:43 AM | How Important To Interventional Outcomes Is Leaving No Foreign Body Or Metal Behind In The Artery: How Can It Be Achieved |
| Presenter(s):Giancarlo Biamino, MD, PhD / Dierk Scheinert, MD | |
| View Abstract | |
| 11:44 AM - 11:49 AM | Variable And High Total Costs For Caring For CLI Patients: What Can Be Done To Cut Costs Without Impairing Patient Care |
| Presenter(s):Timothy M. Sullivan, MD | |
| View Abstract | |
| 11:50 AM - 12:00 PM | Panel Discussion |
| 12:00 PM - 1:00 PM | Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 12 | |
| SESSION 13 SCHEDULE | |
|
Tuesday
SESSION 13:
IN HONOR OF JOHN J. BERGAN, MD: MORE LOWER EXTREMITY ISCHEMIA TREATMENT – ROLE OF OPEN SURGERY; IN STENT RESTENOSIS (ISR) MANAGEMENT – DEBs, DESs, ATHERECTOMY
Moderators:Samuel R. Money, MD, MBA / Barry T. Katzen, MD
|
|
| x | |
| ROLE OF OPEN SURGERY | |
| 1:00 PM - 1:05 PM | Extreme Distal Vein Bypasses After Failed Endovascular Treatments |
| Presenter(s):Giustino Marcucci, MD | |
| View Abstract | |
| 1:06 PM - 1:11 PM | Pedal Bypass With Deep Venous Arterialization: Long-Term Results And Hemodynamic Changes Are Surprisingly Good: Is It An Option After Failed Arterial Bypasses And Endovascular Treatments |
| Presenter(s):Pramook Mutirangura, FRCS (Edinburgh) | |
| View Abstract | |
| 1:12 PM - 1:17 PM | Endovascular vs. Open Treatments For Lower And Upper Extremity CLI: How To Avoid Failure And Bad Outcomes |
| Presenter(s):Francesco Spinelli, MD | |
| View Abstract | |
| 1:18 PM - 1:23 PM | DEBATE: Endovascular Treatment First In All Patients With CLI Is Best |
| Presenter(s):Craig M. Walker, MD | |
| View Abstract | |
| 1:24 PM - 1:29 PM | DEBATE: Open Surgical Treatment First Is Best For Some CLI Patients: Which Ones And Why |
| Presenter(s):Michael S. Conte, MD | |
| View Abstract | |
| 1:30 PM - 1:35 PM | What Is The Best Treatment Strategy For CLI Patients In Terms Of Outcomes And Cost: When Open First, When Endo First |
| Presenter(s):Timothy M. Sullivan, MD | |
| View Abstract | |
| 1:36 PM - 1:42 PM | Panel Discussion |
| DEBS AND TREATMENT OF ISR | |
| Moderator(s): Giancarlo Biamino, MD, PhD / Michael B. Silva, Jr., MD | |
| 1:43 PM - 1:48 PM | Importance Of Technique In Avoiding Dissection With PTA Using DEBs And Standard Balloons: Does Good Flow Matter: How To Know: When Are Stents Really Necessary |
| Presenter(s):Fabrizio Fanelli, MD, EBIR | |
| View Abstract | |
| 1:49 PM - 1:54 PM | How To Cross And Recanalize Chronically Occluded Stents: Stent Puncture And The Radiofrequency PowerWire Can Be Helpful: Technical Tips |
| Presenter(s):Marcelo Guimaraes, MD | |
| View Abstract | |
| 1:55 PM - 2:00 PM | Treatment Of ISR: DEBs Are OK If The Lesion Is Just Intimal Hyperplasia: A Stent Is Required If The Lesion Is Severely Calcified |
| Presenter(s):Dierk Scheinert, MD | |
| View Abstract | |
| 2:01 PM - 2:06 PM | DEBATE: Laser Atherectomy And Stent Graft vs. Laser Atherectomy And DEB For ISR: Which Is Best And Why Debulking Is Essential |
| Presenter(s):Jos C. van den Berg, MD, PhD | |
| View Abstract | |
| 2:07 PM - 2:12 PM | DEBATE: For ISR, POBA vs. DEB vs. DES vs. Covered Stent: 1-Year Results Of The FAIR Trial With The IN.PACT Admiral DEB: Debulking Is Not Necessary |
| Presenter(s):Hans Krankenberg, MD | |
| View Abstract | |
| 2:13 PM - 2:18 PM | The Ocelot OCT Catheter For Crossing CTOs And The Next Generation Atherectomy Device (Phoenix): How Are They Better And In Which Arteries |
| Presenter(s):James F. McKinsey, MD | |
| View Abstract | |
| 2:19 PM - 2:24 PM | How Well Do Paclitaxel Coated DEBs Work For ISR In CLI Patients With Diabetes: 3-Year Results From The DEBATE RCT |
| Presenter(s):Francesco Liistro, MD | |
| View Abstract | |
| 2:25 PM - 2:30 PM | In Memoriam And Recognition Of 5 Giants In Vascular Surgery Who Are No Longer With Us: John Bergan, James DeWeese, Roy Greenberg, Robert Rutherford And David Sumner |
| Presenter(s):Jerry Goldstone, MD, FACS, FRCSEd | |
| View Abstract | |
| 2:31 PM - 2:38 PM | Panel Discussion |
| END OF SESSION 13 | |
| SESSION 14 SCHEDULE | |
|
Tuesday
SESSION 14:
NEW DEVELOPMENTS WITH STENT-GRAFTS FOR OCCLUSIVE DISEASE AND ISR
Moderators:Gary Giangola, MD
|
|
| x | |
| 2:38 PM - 2:43 PM | Use Of Stent-Grafts To Avoid Rupture And Embolization In Endovascular Treatment Of Complex Iliac Artery Occlusive Disease |
| Presenter(s):Maria Antonella Ruffino, MD | |
| View Abstract | |
| 2:44 PM - 2:49 PM | DEBATE: For Long SFA Occlusions DEBs Or Viabahn Propaten Stent-Grafts Are The Best Treatment With The Best Outcomes: Will Drug Coating Tips To Stent-Grafts Improve Results: Will They Be Available |
| Presenter(s):Thomas Zeller, MD | |
| View Abstract | |
| 2:50 PM - 2:55 PM | DEBATE: For Long SFA Occlusions Zilver PTX DESs Are The Best Treatment With The Best Results |
| Presenter(s):Michael D. Dake, MD | |
| View Abstract | |
| 2:56 PM - 3:01 PM | Technical Considerations For Optimal Use Of Viabahn Covered Stents For Long SFA Occlusive Lesions: Lessons Learned From The VIPER And VIASTAR Trials |
| Presenter(s):Dennis R. Gable, MD, FACS | |
| View Abstract | |
| 3:02 PM - 3:07 PM | 2-Year Results Of The RELINE Trial Comparing Viabahn Stent-Grafts To POBA For ISR Show Durable Benefits To Endograft Treatment |
| Presenter(s):Marc Bosiers, MD / Koen Deloose, MD | |
| View Abstract | |
| 3:08 PM - 3:13 PM | Interim Analysis Of The SUPER B Trial Comparing Heparin Bonded Viabahn Endografts To Vein Bypasses For SFA Occlusive Disease |
| Presenter(s):Michel M.P. Reijnen, MD, PhD | |
| View Abstract | |
| 3:14 PM - 3:19 PM | Covered Balloon Expandable Endovascular Graft Reconstruction Of The Aortic Bifurcation (CERAB Procedure) For Aorto-Iliac Occlusive Disease: 2-Year Results And Hemodynamic And Other Advantages |
| Presenter(s):Peter C.J. Goverde, MD | |
| View Abstract | |
| 3:20 PM - 3:26 PM | Panel Discussion |
| 3:26 PM - 3:38 PM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 14 | |
| SESSION 15 SCHEDULE | |
|
Tuesday
SESSION 15:
NEW DEVELOPMENTS IN THE TREATMENT OF ACUTE LOWER EXTREMITY ISCHEMIA (ALI) AND INTERMITTENT CLAUDICATION
Moderators:John B. Chang, MD / Patrick J. Lamparello, MD
|
|
| x | |
| ACUTE LOWER EXTREMITY ISCHEMIA | |
| 3:38 PM - 3:43 PM | How To Avoid Groin Incisions In Hostile Groins When Performing Femoral Embolectomy |
| Presenter(s):Rajiv Parakh, MBBS, MS, FRCS | |
| View Abstract | |
| 3:44 PM - 3:49 PM | Percutaneous Endovascular Thrombosuction: Devices, Techniques, Indications And Results |
| Presenter(s):Athanasios Katsargyris, MD / Eric L.G. Verhoeven, MD, PhD | |
| View Abstract | |
| 3:50 PM - 3:55 PM | Advantages To Indigo Mechanical Thrombectomy For ALI: Device And Technique |
| Presenter(s):Claudio J. Schonholz, MD | |
| View Abstract | |
| 3:56 PM - 4:01 PM | DEBATE: Endovascular Treatments Can Treat Almost All Patients With ALI |
| Presenter(s):Mehdi H. Shishehbor, DO, MPH, PhD | |
| View Abstract | |
| 4:02 PM - 4:07 PM | DEBATE: Some Patients With ALI Require Open Surgical Treatment – Either A Bypass Or Open Thrombectomy: Which Patients |
| Presenter(s):Joseph L. Mills, MD | |
| View Abstract | |
| 4:08 PM - 4:13 PM | Young Athletes With ALI Should Have An Endovascular First Approach: What Are The Causes Of The ALI |
| Presenter(s):Werner Lang, MD | |
| View Abstract | |
| 4:14 PM - 4:19 PM | Cancer And ALI: A Deadly Combination: Why |
| Presenter(s):Cynthia K. Shortell, MD | |
| View Abstract | |
| 4:20 PM - 4:25 PM | With ALI: When Endo; When Open: What Are The Mid-Term Outcomes |
| Presenter(s):Rabih A. Chaer, MD | |
| View Abstract | |
| NEW DATA REGARDING INTERMITTENT CLAUDICATION AND ITS TREATMENT | |
| 4:26 PM - 4:31 PM | Current Drug And Non-Interventional Treatments For Intermittent Claudication: Are They Effective |
| Presenter(s):Jeffrey S. Berger, MD, MS, FAHA, FACC | |
| View Abstract | |
| 4:32 PM - 4:37 PM | For Intermittent Claudication: Immediate Treatment vs. Delayed Treatment vs. No Treatment: Which Is Best |
| Presenter(s):Gregory L. Moneta, MD | |
| View Abstract | |
| 4:38 PM - 4:43 PM | Endovascular vs. Exercise Treatment For Intermittent Claudication: Which Is Best |
| Presenter(s):Jonathan D. Beard, ChM, MEd, FRCS | |
| View Abstract | |
| 4:44 PM - 4:50 PM | Panel Discussion |
| END OF SESSION 15 | |
| SESSION 16 SCHEDULE | |
|
Tuesday
SESSION 16:
NEW DEVELOPMENTS IN CHRONIC CLI AND ITS TREATMENTS: THE ANGIOSOME CONCEPT – PROS AND CONS
Moderators:Keith D. Calligaro, MD / Peter F. Lawrence, MD
|
|
| x | |
| 4:50 PM - 4:55 PM | Advantages Of New SVS Lower Extremity Threatened Limb Classification System For Risk Stratification Based On Wound, Ischemia And Foot Infection |
| Presenter(s):Joseph L. Mills, MD / Michael S. Conte, MD | |
| View Abstract | |
| 4:56 PM - 5:01 PM | Advantages Of And Indications For The Supera Stent – A Vascular Mimetic Implant With Special Properties: High Radial Strength, Low Chronic Outward Force: Tips And Tricks For Implanting And Using |
| Presenter(s):Peter C.J. Goverde, MD | |
| View Abstract | |
| 5:02 PM - 5:07 PM | 3-Year Results With The Supera Interwoven Biomimetic Stent For Femoro-Popliteal Lesions Based On The SUPER B Trial: Why Is This Stent Better Than Others |
| Presenter(s):Lawrence A. Garcia, MD / Kenneth Rosenfield, MD / Dierk Scheinert, MD | |
| View Abstract | |
| 5:08 PM - 5:13 PM | How To Measure Success And Failure With Interventional Treatments For Lower Extremity Ischemia: The Difference Between Thrombosis And Occlusion |
| Presenter(s):Kenneth Ouriel, MD, MBA | |
| View Abstract | |
| 5:14 PM - 5:19 PM | Lower Extremity Outcomes With Fancy Endovascular Devices: We Should Remain Skeptical And Look At The Data |
| Presenter(s):Scott L. Stevens, MD | |
| View Abstract | |
| 5:20 PM - 5:25 PM | Is Directional Atherectomy (Silverhawk Or Turbohawk) With DEB, Better Than DEB Alone: Based On The DEFINITIVE AR RCT: 1-Year Results |
| Presenter(s):Gunnar Tepe, MD / Thomas Zeller, MD | |
| View Abstract | |
| PROS AND CONS OF THE ANGIOSOME CONCEPT | |
| 5:26 PM - 5:31 PM | DEBATE: The Angiosome Concept Is Necessary And Critical In Diabetic/CLI Patients |
| Presenter(s):Richard F. Neville, MD / Anton N. Sidawy, MD, MPH | |
| View Abstract | |
| 5:32 PM - 5:37 PM | DEBATE: The Angiosome Concept Need Not Be Followed In Diabetic Patients With CLI |
| Presenter(s):Ignacio Escotto, MD | |
| View Abstract | |
| 5:38 PM - 5:43 PM | Is The Angiosome Concept Real In Determining Limb Salvage: Results Of A 2-Center Study |
| Presenter(s):Jean-Baptiste Ricco, MD, PhD | |
| View Abstract | |
| 5:44 PM - 5:49 PM | Perfusion Measurements Before And After Tibial PTA Do Not Support The Angiosome Concept |
| Presenter(s):Werner Lang, MD | |
| View Abstract | |
| 5:50 PM - 5:55 PM | Assessing Pedal Microcirculation With An Angiographic Wound Blush: Successful Revascularization And Wound Healing Can Occur Beyond Angiosomes And Beyond Pedal Loop Patency: Angiosomes Differ In Various Patients And Are Not The Holy Grail |
| Presenter(s):John H. Rundback, MD, FSIR, FAHA | |
| View Abstract | |
| 5:56 PM - 6:01 PM | There Is Still A Role For Primary Major Amputation For CLI: When Is It Indicated |
| Presenter(s):Jonathan D. Beard, ChM, MEd, FRCS | |
| View Abstract | |
| 6:02 PM - 6:10 PM | Panel Discussion End of Program B |
| END OF SESSION 16 | |
| SESSION 17 SCHEDULE | |
|
Tuesday
SESSION 17:
NATURAL HISTORY, BEST MEDICAL TREATMENT, PREVENTION OF ARTERIOSCLEROSIS AND ITS COMPLICATIONS
Moderators:Bruce A. Perler, MD, MBA / Keith D. Calligaro, MD
|
|
| x | |
| 6:43 AM - 6:48 AM | Can Medical Treatment Slow The Growth Of Small AAAs |
| Presenter(s):Frank A. Lederle, MD | |
| View Abstract | |
| 6:49 AM - 6:54 AM | Are There New Medical Techniques For Limiting AAA Growth With Drugs (Telmisartan) And Cell Therapy: How Can They Work |
| Presenter(s):Ronald L. Dalman, MD | |
| View Abstract | |
| 6:55 AM - 7:00 AM | Are Statins Decreasing The AAA Rupture Rate: Results From A Danish Nationwide Population-Based Study |
| Presenter(s):Jes S. Lindholt, MD | |
| View Abstract | |
| 7:01 AM - 7:06 AM | A New Agent PCSK9 To Lower LDL: How Low Can LDL Go And Is It Safe |
| Presenter(s):Ron Waksman, MD | |
| View Abstract | |
| 7:07 AM - 7:12 AM | What Is The Association Between The A/B Index And MI And Stroke Risk: Can It Be Altered; What Is The Association Between Obesity And Vascular Disease In Various Vascular Beds: When Is Being Fat Good |
| Presenter(s):Caron B. Rockman, MD | |
| View Abstract | |
| 7:13 AM - 7:18 AM | DEBATE: Statins Have No Role To Play In Primary Prevention And Should Be Avoided In Most Patients |
| Presenter(s):Sherif Sultan, MD, FRCS, EBQS-VASC | |
| View Abstract | |
| 7:19 AM - 7:24 AM | DEBATE: Nonsense: Statins Are A Game Changer, A Miracle Drug: They Should Be Used More Widely In Primary Prevention: Optimal Dosage Of Which Drug |
| Presenter(s):Bruce A. Perler, MD, MBA | |
| View Abstract | |
| 7:25 AM - 7:30 AM | Statins In Vascular Patients: Are There Non-Responders And Responders – How To Tell And What To Do With Non-Responders: What To Do When Patients Have “Apparent Toxicity”: How To Load Preop And Preprocedurally |
| Presenter(s):Don Poldermans, MD | |
| View Abstract | |
| 7:31 AM - 7:36 AM | Optimal Beta Blocker Management In Patients Requiring Vascular Surgery Or Intervention: Current Facts And Optimal Dosing And Drug |
| Presenter(s):Jan M.M. Heyligers, MD, PhD, FEBVS | |
| View Abstract | |
| 7:35 AM - 7:45 AM | Panel Discussion |
| END OF SESSION 17 | |
| SESSION 18 SCHEDULE | |
|
Tuesday
SESSION 18:
INTERVENTIONAL TREATMENT OF HYPERTENSION AND OTHER MEDICAL DISEASES – RENAL DENERVATION
Moderators:Horst Sievert, MD / Frank J. Veith, MD
|
|
| x | |
| 7:45 AM - 7:50 AM | Role Of Sympathetic Nervous System In Cardiovascular Function And Hypertension: How Does Renal Artery Denervation Produce A Drop In Blood Pressure |
| Presenter(s):John W. Osborn, PhD | |
| View Abstract | |
| 7:51 AM - 7:56 AM | Renal Denervation For Drug Resistant Hypertension: Does It Work: Many Trials Say It Does And Yet SIMPLICITY III Says It Does Not: Does The Emperor Have No Clothes |
| Presenter(s):Ron Waksman, MD | |
| View Abstract | |
| 7:57 AM - 8:02 AM | Collateral Benefits Of Renal Denervation: Reasons Why SIMPLICITY III Did Not Meet Its Goals: Will Other Techniques To Decrease Sympathetic Tone And Blood Pressure Work: How About Barostimulation (Rheos Device) And A-V Fistula (With ROX Device) |
| Presenter(s):Krishna J. Rocha-Singh, MD | |
| View Abstract | |
| 8:03 AM - 8:08 AM | Unanswered Questions About Renal Denervation After SIMPLICITY III; What Other Devices Are Being Evaluated And Will They Be Effective (Northwind, Paradise, Ultrasound, Etc.) |
| Presenter(s):Horst Sievert, MD | |
| View Abstract | |
| 8:09 AM - 8:14 AM | Where Do We Go After SIMPLICITY III: Is There Evidence That Renal Denervation Will Work: Are There Other Devices And Technology And What Do They Offer |
| Presenter(s):Yvonne Bausback, MD / Dierk Scheinert, MD | |
| View Abstract | |
| 8:15 AM - 8:20 AM | What Is Required To Support A Renal Denervation Practice For Resistant Hypertension And Other Devices: Should Vascular Surgeons Consider Setting Up Such A Program Before Everyone Else Jumps On The Bandwagon |
| Presenter(s):Christoph A. Nienaber, MD, PhD | |
| View Abstract | |
| 8:21 AM - 8:26 AM | Defining Real Resistant Hypertension: Are There Responders And Non-Responders To Renal Denervation And Can RF (Radiofrequency) Treatment Injure The Renal Arteries |
| Presenter(s):Melvin D. Lobo, MBChB, PhD, FRCP | |
| View Abstract | |
| 8:27 AM - 8:32 AM | Failure Of SIMPLICITY III To Demonstrate Efficacy Of Renal Denervation By Endovascular RF Could Be Due To Nerve Distribution Far From The Renal Artery Lumen: Is Surgical Perirenal Neurolysis Possible And What Is Its Effect |
| Presenter(s):Juan C. Parodi, MD | |
| View Abstract | |
| 8:33 AM - 8:39 AM | Panel Discussion |
| END OF SESSION 18 | |
| SESSION 19 SCHEDULE | |
|
Tuesday
SESSION 19:
TREATMENT AND AVOIDANCE OF COMPLICATIONS; ENDOLEAKS AND THEIR MANAGEMENT
Moderators:Timur P. Sarac, MD / Frans L. Moll, MD, PhD
|
|
| x | |
| MANAGEMENT OF COMPLICATIONS | |
| 8:39 AM - 8:44 AM | Access Site Complications After Non-Cardiac Interventions: Incidence, Predictive Factors, How To Prevent And Outcomes: Value Of Routine Ultrasound Guidance |
| Presenter(s):Mark W. Mewissen, MD | |
| View Abstract | |
| 8:45 AM - 8:50 AM | Endovascular Treatment Of Anastomotic Complications After Open Surgery – Including False Aneurysms And Infections |
| Presenter(s):Jos C. van den Berg, MD, PhD | |
| View Abstract | |
| 8:51 AM - 8:56 AM | Endovascular Treatment Of Tracheo-Innominate Artery Fistulas: How To Do It Successfully |
| Presenter(s):Gabriel Szendro, MD | |
| View Abstract | |
| 8:57 AM - 9:02 AM | Successful Treatment Of An Innominate Artery-Tracheal Fistula With A Modified Endograft |
| Presenter(s):Evan C. Lipsitz, MD | |
| View Abstract | |
| NEW DEVELOPMENTS IN ENDOLEAK MANAGEMENT | |
| 9:03 AM - 9:08 AM | What Is Currently The Best Information About The Significance Of TypeType 2 Endoleaks: How Are They Best Diagnosed And Treated |
| Presenter(s):Kim J. Hodgson, MD | |
| View Abstract | |
| 9:09 AM - 9:14 AM | Conservative (Observational) Management Is Appropriate For Some Primary Type 1A Endoleaks After EVAR And TEVAR Procedures: Which Ones |
| Presenter(s):Frans L. Moll, MD, PhD | |
| View Abstract | |
| 9:15 AM - 9:20 AM | What Are The Real Causes Of Endotension: Can A Hypervascular AAA Sac Wall Cause It: How To Diagnose And Treat It |
| Presenter(s):Timur P. Sarac, MD | |
| View Abstract | |
| 9:21 AM - 9:26 AM | Type 1 Endoleaks After EVAR: Role Of Onyx In Fixing Them: Tips And Tricks For Its Use And How To Diagnose And Treat Those That Masquerade As Type 2 Endoleaks |
| Presenter(s):Robert A. Morgan, MD | |
| View Abstract | |
| 9:27 AM - 9:32 AM | What Is The Real Long-Term Outcome Of Type 2 Endoleaks: Based On A Single Center And The OVER Trial Experience |
| Presenter(s):Wei Zhou, MD | |
| View Abstract | |
| 9:33 AM - 9:38 AM | Open Aortic Wrap For Persistent Type 1A Endoleak: Technical Tips And Results |
| Presenter(s):Ross Milner, MD | |
| View Abstract | |
| 9:39 AM - 9:44 AM | Accurate Endoleak Detection And Characterization Using Temporal Information From Contrast Enhanced Ultrasound |
| Presenter(s):S. Rao Vallabhaneni, MD, FRCS | |
| View Abstract | |
| 9:45 AM - 9:52 AM | Panel Discussion |
| 9:52 AM - 10:05 AM | Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 19 | |
| SESSION 20 SCHEDULE | |
|
Tuesday
SESSION 20:
OPTIMAL PERIPROCEDURAL MEDICAL MANAGEMENT IN VASCULAR PATIENTS; SOME INTERESTING HISTORY AND TECHNOLOGY; THE CCSVI FOR MULTIPLE SCLEROSIS (MS) CONTROVERSY
Moderators:Caron B. Rockman, MD / K. Craig Kent, MD
|
|
| x | |
| PERIPROCEDURAL MANAGEMENT, INTERESTING HISTORY AND TECHNOLOGY | |
| 10:05 AM - 10:10 AM | Periop And Periprocedural Care Is Key For Vascular Patients: What Is Optimal Antiplatelet Treatment; Statin Dosage, Drugs And Loading; And Beta Blockade |
| Presenter(s):Caron B. Rockman, MD / Jeffrey S. Berger, MD, MS, FAHA, FACC | |
| View Abstract | |
| 10:11 AM - 10:16 AM | Scandalous High Long-Term Mortality After EVAR: It Is Due To MD Ignorance Regarding Statins And Other Medical Treatment: The AAA Is Fixed But MIs Kill: Statins Should Be In The Drinking Water |
| Presenter(s):Matt M. Thompson, MD | |
| View Abstract | |
| 10:17 AM - 10:22 AM | Heparin Management During Open AAA Repair: Is Heparin Necessary For Elective Or Ruptured AAA Repair |
| Presenter(s):Arno M. Wiersema, MD | |
| View Abstract | |
| 10:23 AM - 10:28 AM | How Do Statins Influence Long-Term Restenosis And Cardiovascular Events (Stroke And MI) After CEA And After CAS |
| Presenter(s):Christos D. Liapis, MD | |
| View Abstract | |
| 10:29 AM - 10:34 AM | Tales From The Crypt: 5000-Year-Old History Of Atherosclerosis (ASO): What It Tells Us About ASO Today |
| Presenter(s):Christopher K. Zarins, MD | |
| View Abstract | |
| 10:35 AM - 10:40 AM | What Andreas Gruntzig Said 30 Years Ago And Its Relevance Today |
| Presenter(s):Sigrid Nikol, MD | |
| View Abstract | |
| 10:41 AM - 10:46 AM | Shock Wave Lithoplasty For Treating Severely Calcified Occlusive Lesions: Theory And 30-Day CE Mark Study Results |
| Presenter(s):Andrew Holden, MBChB | |
| View Abstract | |
| 10:47 AM - 10:53 AM | Panel Discussion |
| THE CCSVI FOR MS CONTROVERSY | |
| Moderator(s): Lindsay Machan, MD / Manish Mehta, MD, MPH | |
| 10:53 AM - 10:58 AM | What Is New In CCSVI For MS: The Positive Evidence Mounts: How To Select Patients: Can Brain Perfusion Be Improved: Is Open Vein Repair Ever Needed |
| Presenter(s):Paolo Zamboni, MD | |
| View Abstract | |
| 10:59 AM - 11:04 AM | Vein PTA Helps Selected MS Patients With CCSVI: There Is No Doubt: Stem Cell Therapy May Also Be Beneficial |
| Presenter(s):Ivo Petrov, MD, PhD | |
| View Abstract | |
| 11:05 AM - 11:10 AM | The Omohyoid Muscle Can Be A Cause Of Venous Compression Leading To CCSVI: Documentation And Relief By Resection |
| Presenter(s):Alberto Lomeo, MD | |
| View Abstract | |
| 11:11 AM - 11:16 AM | Regarding CCSVI And MS, A Skeptic’s View |
| Presenter(s):J. David Spence, MD | |
| View Abstract | |
| 11:17 AM - 11:22 AM | Despite Some Questions, There Is Still A Relationship Between CCSVI And MS And An Opportunity For A Positive Effect From Endovascular Treatment |
| Presenter(s):Michael D. Dake, MD | |
| View Abstract | |
| 11:23 AM - 11:28 AM | The Proper Technique For Venoplasty For CCSVI As A Contributory Cause Of MS: Variability In Technique May Account For Variable Results |
| Presenter(s):Donald B. Reid, MD | |
| View Abstract | |
| 11:29 AM - 11:34 AM | Is The CCSVI Concept In MS Valid: Results Of A Meta-analysis |
| Presenter(s):Jean-Baptiste Ricco, MD, PhD | |
| View Abstract | |
| 11:35 AM - 11:40 AM | The Presence Of Extracranial Venous Narrowing Is The Same In MS Patients And Normal Controls |
| Presenter(s):Lindsay Machan, MD | |
| View Abstract | |
| 11:41 AM - 11:46 AM | Update On The RCT Of Venous Balloon Angioplasty vs. Venography Placebo: What Does It Tell Us |
| Presenter(s):L. Nelson Hopkins, MD / Robert Zivadinov, MD, PhD, FAAN | |
| View Abstract | |
| 11:47 AM - 12:00 PM | Panel Discussion |
| 12:00 PM - 1:00 PM | Lunch Break – Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 20 | |
| SESSION 21 SCHEDULE | |
|
Tuesday
SESSION 21:
ISSUES: VARIABLE VASCULAR CARE, GOVERNMENT, FDA, HEALTH CARE REFORM, ETHICS
Moderators:Kenneth Ouriel, MD, MBA / Robert M. Zwolak, MD, PhD
|
|
| x | |
| 1:00 PM - 1:05 PM | How To Increase Public Awareness Of Vascular Disease And The Role Of The Specialty Of Vascular Surgery |
| Presenter(s):Robert B. McLafferty, MD | |
| View Abstract | |
| 1:06 PM - 1:11 PM | Disparity Of Vascular Care: Variations Of Index Vascular Procedures In Different Hospitals And Different Locations: Why |
| Presenter(s):Mohammad H. Eslami, MD, RVT | |
| View Abstract | |
| 1:12 PM - 1:17 PM | DEBATE: The Changes In The FDA Process For Cardiovascular Device Evaluation And Approval Will Increase US Access To Safe And Effective Devices – And Make It More Like Other Civilized Countries |
| Presenter(s):Dorothy B. Abel, BSBME / J. Pablo Morales, MD | |
| View Abstract | |
| 1:18 PM - 1:23 PM | DEBATE: Are The FDA Changes Really Going To Facilitate New Device Evaluation And Availability In The US: The Difficulty Lies With Congress, Not The FDA |
| Presenter(s):Ron Waksman, MD | |
| View Abstract | |
| 1:24 PM - 1:29 PM | Template For An IDE For Physician Modified Endografts |
| Presenter(s):Patrick W. Kelly, MD / Rodney A. White, MD / Dorothy B. Abel, BSBME | |
| View Abstract | |
| 1:30 PM - 1:35 PM | Perverse Incentives To Perform Vascular Procedures, And Pay For Performance Measurements Are Bad: How To Fix The Problems |
| Presenter(s):Timothy F. Kresowik, MD | |
| View Abstract | |
| 1:36 PM - 1:41 PM | Panel Discussion |
| IMPACT OF OBAMACARE | |
| 1:42 PM - 1:47 PM | Impact Of Obamacare (ACA) On American Medicine And Our Country: I Thought It Was Bad But I Never Realized How Bad |
| Presenter(s):Clifford J. Buckley, MD | |
| View Abstract | |
| 1:48 PM - 1:53 PM | The Train Is Coming At You: What Will The Cost Of Obamacare Be To Vascular Patients And Vascular Surgeons |
| Presenter(s):James H. Black III, MD | |
| View Abstract | |
| 1:54 PM - 1:59 PM | Detrimental Effects Of The ACA And ACOs On The Work Environment Of Vascular Surgeons And Their Freedom To Provide The Best Care: Are Doctors-Unions A Legal And Inevitable Solution |
| Presenter(s):Timothy M. Sullivan, MD | |
| View Abstract | |
| 2:00 PM - 2:05 PM | The Impact Of The ACA On The Medical Device Industry: What Harm Or Benefit Will It Cause: How Are Things Working Out |
| Presenter(s):Kem Hawkins, MBA | |
| View Abstract | |
| 2:06 PM - 2:11 PM | Impact Of Obamacare On Vascular Surgery In 2014 And 2015 |
| Presenter(s):Robert M. Zwolak, MD, PhD | |
| View Abstract | |
| 2:12 PM - 2:17 PM | Heart And Vascular Care In The Era Of Health Reform And The ACA: Where Are We Headed And How To Survive |
| Presenter(s):John H. Furtek, BS, RT(r) | |
| View Abstract | |
| 2:18 PM - 2:23 PM | The ACA Says It's Willing To Pay For Disease Prevention: Why That Is Not True |
| Presenter(s):Clifford M. Sales, MD, MBA / Patricia Davidson, RN | |
| View Abstract | |
| 2:24 PM - 2:30 PM | Panel Discussion |
| END OF SESSION 21 | |
| SESSION 22 SCHEDULE | |
|
Tuesday
SESSION 22:
ISSUES RELATED TO INDEPENDENCE FOR VASCULAR SURGERY, RESIDENCY TRAINING, BUSINESS, REIMBURSEMENT, COST/BENEFIT, CONFLICT OF INTEREST (COI)
Moderators:Michel Makaroun, MD / Karl A. Illig, MD
|
|
| x | |
| INDEPENDENCE AND GOVERNANCE ISSUES FOR VASCULAR SURGERY | |
| 2:30 PM - 2:35 PM | What Have Been The Beneficial Effects For Patients And Vascular Surgeons Of Vascular Surgery Being Recognized As An Independent Specialty In Switzerland |
| Presenter(s):Jürg Schmidli, MD | |
| View Abstract | |
| 2:36 PM - 2:41 PM | How Has Independence Helped Vascular Surgery And Its Patients In Sweden |
| Presenter(s):Anders Wanhainen, MD, PhD | |
| View Abstract | |
| 2:42 PM - 2:47 PM | How Has Independence For Its Governing Bodies Helped Vascular Surgery And Its Patients In The UK |
| Presenter(s):George Hamilton, MD; FRCS | |
| View Abstract | |
| 2:48 PM - 2:53 PM | How Has The European Vascular Surgery FEBVS Exam Contributed To Vascular Surgery’s Independence In Europe And Improved Patient Care |
| Presenter(s):David McLain, FEBVS | |
| View Abstract | |
| 2:54 PM - 2:59 PM | The American Board of Vascular Surgery (ABVS) And The Vascular Surgery Board of The American Board of Surgery (VSB of ABS): Is There More |
| Presenter(s):James C. Stanley, MD | |
| View Abstract | |
| RESIDENCY TRAINING IN VASCULAR SURGERY | |
| 3:00 PM - 3:05 PM | Update On The Current Status Of 0+5 Vascular Surgery Residency Training |
| Presenter(s):Murray L. Shames, MD / Karl A. Illig, MD | |
| View Abstract | |
| 3:06 PM - 3:11 PM | The New Residency Review Committee-Surgery (RRC-S) Vascular Criteria For Training In General And Vascular Surgery: What Will The Case Requirements Be: Is It Good For Vascular Surgery |
| Presenter(s):Ronald L. Dalman, MD | |
| View Abstract | |
| BUSINESS, REIMBURSEMENT AND COST ISSUES | |
| 3:12 PM - 3:17 PM | What Is Happening With Vascular Procedural Reimbursement In 2015: How Bad Will It Be |
| Presenter(s):Sean P. Roddy, MD | |
| View Abstract | |
| 3:18 PM - 3:23 PM | Current Business Considerations In Medicine And Reimbursement: How Can We Deal With Them |
| Presenter(s):Glenn Jacobowitz, MD / Mark A. Adelman, MD | |
| View Abstract | |
| 3:24 PM - 3:29 PM | What Vascular Specialists Can Do To Protect Their Assets From Frivolous Law Suits Related To Malpractice And Other Issues |
| Presenter(s):Hillel Presser, Esq., MBA | |
| View Abstract | |
| 3:30 PM - 3:35 PM | Heart And Vascular Institutes: Boons Or Busts For Vascular Surgeons: What Are The Dangers |
| Presenter(s):Timur P. Sarac, MD | |
| View Abstract | |
| 3:36 PM - 3:41 PM | The FAST Vascular Concept: A Method To Reduce Resource Utilization With EVAR And Open Repair Of AAAs |
| Presenter(s):Sebastian E. Debus, MD, PhD | |
| View Abstract | |
| 3:42 PM - 3:47 PM | What Are The Drivers Of Cost For Treating SFA Occlusive Disease And AAAs: How Can These Costs Be Decreased |
| Presenter(s):Richard J. Powell, MD | |
| View Abstract | |
| 3:48 PM - 3:53 PM | Setting Up A Functional Hybrid Room Involves More Than You Think: What Resources, Personnel And Costs Must Be Involved |
| Presenter(s):Rodney A. White, MD | |
| View Abstract | |
| 3:54 PM - 4:04 PM | Panel Discussion And Break Visit Exhibits And Pavilions (2nd and 3rd Floors) |
| END OF SESSION 22 | |
| SESSION 23 SCHEDULE | |
|
Tuesday
SESSION 23:
OUTPATIENT TREATMENT, IMPROVING CARE, RCTs, REGISTRIES
Moderators:Mark A. Adelman, MD / Jack L. Cronenwett, MD
|
|
| x | |
| 4:04 PM - 4:09 PM | Advantages Of An Outpatient Endovascular Center To An Academic Vascular Surgery Department |
| Presenter(s):Mark A. Adelman, MD | |
| View Abstract | |
| 4:10 PM - 4:15 PM | What Organization(s) Should Set Standards, Accredit And Regulate Outpatient Vascular And Vein Diagnostic And Treatment Centers – Toward What Goals |
| Presenter(s):Lowell S. Kabnick, MD, RPhS, FACS, FACPh | |
| View Abstract | |
| 4:16 PM - 4:21 PM | The Importance Of Patient Reported Outcome Measures (PROMs) To Vascular Surgeons |
| Presenter(s):Mark J.W. Koelemay, MD, PhD | |
| View Abstract | |
| 4:22 PM - 4:27 PM | Relationship Between Patient Satisfaction And Favorable Surgical Outcomes |
| Presenter(s):K. Craig Kent, MD | |
| View Abstract | |
| 4:28 PM - 4:33 PM | Income vs. Outcomes In Vascular Patients: Low Income Is An Independent Risk Factor For Outcomes: Why |
| Presenter(s):Hence J.M. Verhagen, MD, PhD | |
| View Abstract | |
| 4:34 PM - 4:39 PM | Access To Health Care Does Not Correlate With Limb Salvage In CLI: Race And Socioeconomic Status Do |
| Presenter(s):Michael C. Stoner, MD | |
| View Abstract | |
| 4:40 PM - 4:45 PM | LEAN Principles And Their Application To Vascular Surgery: What Can Toyota Teach Us About Providing Better Vascular Health Care |
| Presenter(s):Tej M. Singh, MD, MBA | |
| View Abstract | |
| EVIDENCE BASED MEDICINE AND RCTS | |
| 4:46 PM - 4:51 PM | Commentary On Evidence Based Medicine And RCTs In Cardiovascular Surgery And Medicine; Not All RCTs Are Holy |
| Presenter(s):Peter Samek, MD, PhD | |
| View Abstract | |
| 4:52 PM - 4:56 PM | RCTs Can Be Underpowered And Futile To Detect Small Effects In Many Instances: Some Examples |
| Presenter(s):Charles C. Miller, PhD | |
| View Abstract | |
| 4:58 PM - 5:03 PM | In The Treatment Of Asymptomatic Carotid Stenosis: How Do RCTs Relate To The Real World: What Are The Pitfalls Of RCTs |
| Presenter(s):Hans-Henning Eckstein, MD, PhD | |
| View Abstract | |
| IMPROVED TECHNOLOGY AND VASCULAR SPECIALISTS' PRACTICES | |
| 5:04 PM - 5:09 PM | How Can Social Media Help Vascular Specialists |
| Presenter(s):Ido Weinberg, MD, MSc | |
| View Abstract | |
| 5:10 PM - 5:15 PM | How A Smart Phone Can Change Your Practice For The Better: How A Computer Analysis Of EKGs Can Give You Ejection Fractions And Ventricular Wall Motion And Do Away With Many Cardiac Echo Studies |
| Presenter(s):Lindsay Machan, MD | |
| View Abstract | |
| 5:16 PM - 5:21 PM | Update On The Status Of The SVS VQI Registry And What It Can Offer Clinically And For Research |
| Presenter(s):Larry W. Kraiss, MD / Jack L. Cronenwett, MD | |
| View Abstract | |
| 5:22 PM - 5:27 PM | Are There Disadvantages To VQI Initiatives: Do They Give Rise To Conflicts |
| Presenter(s):Kenneth Ouriel, MD, MBA | |
| View Abstract | |
| 5:28 PM - 5:34 PM | Panel Discussion |
| END OF SESSION 23 | |
| SESSION 24 SCHEDULE | |
|
Tuesday
SESSION 24:
ISSUES RELATING TO SIMULATION, TRAINING AND EDUCATION
Moderators:Jason T. Lee, MD / Mario Lachat, MD
|
|
| x | |
| SIMULATION, TRAINING AND EDUCATION | |
| 5:34 PM - 5:39 PM | Advantages And Limitations Of Patient Specific Simulator Rehearsal Prior To EVAR And Other Procedures |
| Presenter(s):Isabelle van Herzeele, MD, PhD | |
| View Abstract | |
| 5:40 PM - 5:45 PM | Simulator Training vs. Clinical Invasive Experience: A RCT Showing Benefits Of Case Specific Simulator Training Even With Experienced Operators |
| Presenter(s):Lars B. Lonn, MD, PhD | |
| 5:46 PM - 5:51 PM | New Pathways And Technology To Improve Efficiency And Resource Use In Vascular Practice |
| Presenter(s):Nicholas J.W. Cheshire, MD | |
| View Abstract | |
| 5:52 PM - 5:57 PM | VESAP 3: Where Is It And How Can It Help In MOC And Review For The Vascular Surgery Board Exams |
| Presenter(s):John F. Eidt, MD | |
| View Abstract | |
| 5:58 PM - 6:03 PM | Advances In The Education Of Vascular Surgeons In Complex Endovascular Techniques: The Boot Camp Initiative And Regional Video Conferencing |
| Presenter(s):Mark G. Davies, MD / Alan B. Lumsden, MD, FACS | |
| View Abstract | |
| 6:04 PM - 6:10 PM | Panel Discussion End of Program C |
| END OF SESSION 24 | |